DK65575A - - Google Patents

Info

Publication number
DK65575A
DK65575A DK65575*#A DK65575A DK65575A DK 65575 A DK65575 A DK 65575A DK 65575 A DK65575 A DK 65575A DK 65575 A DK65575 A DK 65575A
Authority
DK
Denmark
Application number
DK65575*#A
Other languages
Danish (da)
Other versions
DK153919C (da
DK153919B (da
Inventor
J M Indelicato
J M Greene
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23765656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK65575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK65575A publication Critical patent/DK65575A/da
Publication of DK153919B publication Critical patent/DK153919B/da
Application granted granted Critical
Publication of DK153919C publication Critical patent/DK153919C/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK065575A 1974-02-22 1975-02-21 Fremgangsmaade til fremstilling af farmaceutiske kompositioner der indeholder toert natrium-7-(d-2-formyloxy-2-phenylacetamido)-3-(1-methyl-1h-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylat DK153919C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US444622A US3928592A (en) 1974-02-22 1974-02-22 Antibiotic pharmaceutical compositions
US44462274 1974-02-22

Publications (3)

Publication Number Publication Date
DK65575A true DK65575A (US20110009641A1-20110113-C00273.png) 1975-10-20
DK153919B DK153919B (da) 1988-09-26
DK153919C DK153919C (da) 1989-02-06

Family

ID=23765656

Family Applications (1)

Application Number Title Priority Date Filing Date
DK065575A DK153919C (da) 1974-02-22 1975-02-21 Fremgangsmaade til fremstilling af farmaceutiske kompositioner der indeholder toert natrium-7-(d-2-formyloxy-2-phenylacetamido)-3-(1-methyl-1h-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylat

Country Status (24)

Country Link
US (1) US3928592A (US20110009641A1-20110113-C00273.png)
JP (1) JPS6119605B2 (US20110009641A1-20110113-C00273.png)
AR (1) AR203895A1 (US20110009641A1-20110113-C00273.png)
AT (1) AT356264B (US20110009641A1-20110113-C00273.png)
BE (1) BE825653A (US20110009641A1-20110113-C00273.png)
CA (1) CA1043261A (US20110009641A1-20110113-C00273.png)
CH (1) CH620929A5 (US20110009641A1-20110113-C00273.png)
CS (1) CS189689B2 (US20110009641A1-20110113-C00273.png)
DD (1) DD117807A5 (US20110009641A1-20110113-C00273.png)
DE (1) DE2506622C2 (US20110009641A1-20110113-C00273.png)
DK (1) DK153919C (US20110009641A1-20110113-C00273.png)
ES (1) ES434976A1 (US20110009641A1-20110113-C00273.png)
FR (1) FR2261772B1 (US20110009641A1-20110113-C00273.png)
GB (1) GB1493676A (US20110009641A1-20110113-C00273.png)
HU (1) HU174129B (US20110009641A1-20110113-C00273.png)
IE (1) IE40671B1 (US20110009641A1-20110113-C00273.png)
IL (1) IL46650A (US20110009641A1-20110113-C00273.png)
NL (1) NL179976C (US20110009641A1-20110113-C00273.png)
PH (1) PH12058A (US20110009641A1-20110113-C00273.png)
PL (1) PL109311B1 (US20110009641A1-20110113-C00273.png)
SE (1) SE406153B (US20110009641A1-20110113-C00273.png)
SU (1) SU659094A3 (US20110009641A1-20110113-C00273.png)
YU (1) YU41875A (US20110009641A1-20110113-C00273.png)
ZA (1) ZA75975B (US20110009641A1-20110113-C00273.png)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054738A (en) * 1975-12-22 1977-10-18 Eli Lilly And Company Sodium cefamandole crystalline forms
JPS5283956A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Antibiotic method and medical composition
JPS5329936A (en) * 1976-08-31 1978-03-20 Takeda Chem Ind Ltd Antibiotic composition
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
JP4873207B2 (ja) * 2001-02-26 2012-02-08 東レ・ファインケミカル株式会社 光学活性カルボン酸クロリドの精製方法
CN100554271C (zh) * 2007-07-27 2009-10-28 苏州中联化学制药有限公司 抗菌素头孢孟多酯钠的合成方法
CN101880290B (zh) * 2010-06-28 2012-03-07 海南新中正制药有限公司 头孢孟多酯钠的制备方法
WO2013057196A1 (en) * 2011-10-20 2013-04-25 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of cefamandole nafate
WO2013057197A1 (en) * 2011-10-20 2013-04-25 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the formylation of cefamandole
US9834567B1 (en) * 2014-12-16 2017-12-05 Tianjin University Crystalline form of cefamandole nafate compound, preparation and preparing method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1767891C3 (de) * 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3641021A (en) * 1969-04-18 1972-02-08 Lilly Co Eli 3 7-(ring-substituted) cephalosporin compounds

Also Published As

Publication number Publication date
ES434976A1 (es) 1976-12-16
SE406153B (sv) 1979-01-29
HU174129B (hu) 1979-11-28
DD117807A5 (US20110009641A1-20110113-C00273.png) 1976-02-05
US3928592A (en) 1975-12-23
DE2506622C2 (de) 1987-02-26
NL179976C (nl) 1986-12-16
SU659094A3 (ru) 1979-04-25
CH620929A5 (US20110009641A1-20110113-C00273.png) 1980-12-31
DE2506622A1 (de) 1975-08-28
NL179976B (nl) 1986-07-16
YU41875A (en) 1982-05-31
FR2261772A1 (US20110009641A1-20110113-C00273.png) 1975-09-19
ZA75975B (en) 1976-09-29
AU7833975A (en) 1976-08-19
JPS50126817A (US20110009641A1-20110113-C00273.png) 1975-10-06
PL109311B1 (en) 1980-05-31
NL7502045A (nl) 1975-08-26
IL46650A (en) 1977-10-31
AR203895A1 (es) 1975-10-31
CA1043261A (en) 1978-11-28
GB1493676A (en) 1977-11-30
IE40671B1 (en) 1979-07-18
ATA128475A (de) 1979-09-15
DK153919C (da) 1989-02-06
AT356264B (de) 1980-04-25
SE7501985L (US20110009641A1-20110113-C00273.png) 1975-08-25
IE40671L (en) 1975-08-22
JPS6119605B2 (US20110009641A1-20110113-C00273.png) 1986-05-17
PH12058A (en) 1978-10-18
IL46650A0 (en) 1975-05-22
FR2261772B1 (US20110009641A1-20110113-C00273.png) 1980-01-04
BE825653A (fr) 1975-08-18
CS189689B2 (en) 1979-04-30
DK153919B (da) 1988-09-26

Similar Documents

Publication Publication Date Title
FR2277017B1 (US20110009641A1-20110113-C00273.png)
FR2266492B3 (US20110009641A1-20110113-C00273.png)
FR2295290B1 (US20110009641A1-20110113-C00273.png)
FR2261772B1 (US20110009641A1-20110113-C00273.png)
FR2268038A1 (US20110009641A1-20110113-C00273.png)
FR2280691B1 (US20110009641A1-20110113-C00273.png)
FR2281170B1 (US20110009641A1-20110113-C00273.png)
FR2259348B1 (US20110009641A1-20110113-C00273.png)
FR2280055B1 (US20110009641A1-20110113-C00273.png)
FR2262522A1 (US20110009641A1-20110113-C00273.png)
FR2290688B1 (US20110009641A1-20110113-C00273.png)
CS174483B1 (US20110009641A1-20110113-C00273.png)
BG22484A1 (US20110009641A1-20110113-C00273.png)
BG21632A1 (US20110009641A1-20110113-C00273.png)
CH1357474A4 (US20110009641A1-20110113-C00273.png)
CH1107074A4 (US20110009641A1-20110113-C00273.png)
BG26152A1 (US20110009641A1-20110113-C00273.png)
BG23188A1 (US20110009641A1-20110113-C00273.png)
AU480209A (US20110009641A1-20110113-C00273.png)
AU479725A (US20110009641A1-20110113-C00273.png)
BG22732A1 (US20110009641A1-20110113-C00273.png)
BG21285A1 (US20110009641A1-20110113-C00273.png)
BG22309A1 (US20110009641A1-20110113-C00273.png)
AU480469A (US20110009641A1-20110113-C00273.png)
AU480580A (US20110009641A1-20110113-C00273.png)

Legal Events

Date Code Title Description
PUP Patent expired